Immunotherapy plus chemo shows promise for tough sarcomas

NCT ID NCT04589741

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy helps people with advanced bone or soft tissue sarcoma live longer without their cancer growing. About 134 participants whose cancer has not responded to standard treatments will be randomly assigned to get either the combo or chemo alone. The study aims to see if the combination improves outcomes like tumor shrinkage and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: toripalimab combined with chemotherapy (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide)
What this could lead to: If successful, this could offer a new treatment option for people with advanced sarcoma who have run out of standard options.
What could go wrong: This is a mid-stage trial with only 134 participants, so results may not apply to everyone. Combining immunotherapy with chemotherapy can increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMA

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.